Sugi Predict

Sugi Predict / Compounds / SCHEMBL560243

SCHEMBL560243

SCHEMBL560243

COC(=O)c1ccc(Cl)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.69
▸ CA2 P00918 4/20 0.69
▸ CA12 O43570 3/20 0.69
▸ CA7 P43166 3/20 0.69
▸ CA9 Q16790 3/20 0.69
▸ CA14 Q9ULX7 3/20 0.69
▸ XDH P47989 2/20 0.69
▸ ALDH1A1 P00352 5/20 0.60
▸ KDM4E B2RXH2 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ GAA P10253 2/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ POLB P06746 1/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ GFER P55789 1/20 0.57
▸ NFKB2 Q00653 1/20 0.57
▸ RELA Q04206 1/20 0.57
▸ FUT7 Q11130 1/20 0.57
▸ MAPT P10636 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208021 0.87 CA12 (0.53) CA1CA2CA12CA7CA9
SCHEMBL30153190 0.85 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL198849 0.85 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL29822834 0.84 ALDH1A1 (0.64) CA1CA2CA12CA7CA9
SCHEMBL5393044 0.84 ALDH1A1 (0.64) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL29360855 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL38624 0.82 CA1 (1.00) CA1CA2CA12CA7CA9
SCHEMBL15099889 0.82 CA1 (0.77) CA1CA2CA12CA7CA9
SCHEMBL70470 0.81 ALDH1A1 (0.65) CA1CA2CA12CA7CA9
SCHEMBL2237689 0.81 ALDH1A1 (0.60) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103073589-A Synthetic method of 1, 2-dioxetane compound UNIV HANGZHOU NORMAL 2013-05-01 — — CN claimed
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2025-10-02 — — US disclosed
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 — — US disclosed
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 — — US disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 — — CN disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 — — EP disclosed
EP-4347036-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 — — EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 — — CN disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 — — US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 — — US disclosed
CN-1481376-A HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS ���ĵ�˹ҩ��¹����޹�˾ 2004-03-10 — — CN disclosed
US-20030213940-A1 Chemiluminescent 1,2-dioxetanes GIRI BRIJ P (US) 2003-11-20 — — US disclosed
EP-1349847-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2003-10-08 — — EP disclosed
WO-2003054506-A2 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ PAL (US) 2003-07-03 — — WO disclosed
US-20020198195-A1 New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-12-26 — — US disclosed
US-6461876-B1 STABLE SPIROFUSED RINGS; DECOMPOSING TO GENERATE LIGHT AND CARBONYL GROUP; HIGH ENERGY; MEDICINE TOBEN, HOWARD R. 2002-10-08 — — US disclosed
WO-2002051831-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-07-04 — — WO disclosed
EP-1112274-A4 CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ P (US) 2002-06-12 — — EP disclosed
EP-1112274-A1 CHEMILUMINESCENT 1,2-DIOXETANES Giri, Brij P. (US) 2001-07-04 — — EP disclosed
WO-2000014092-A1 CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ P (US) 2000-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 CA1 4828/4885CA2 4851/4885CA12 3792/4885
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 CA1 3605/4885CA2 2852/4885CA12 1813/4885
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 CA1 4409/4885CA2 1475/4885CA12 4119/4885
US-20020198195-A1 New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa F9, F11, F5 CA1 4325/4885CA2 2450/4885CA12 3684/4885
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 CA1 4828/4885CA2 4851/4885CA12 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.